Lyn peptide inhibitor acetate
Code | Size | Price |
---|
TAR-TP2008L-1mg | 1mg | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2008L-5mg | 5mg | £313.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2008L-10mg | 10mg | £434.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2008L-25mg | 25mg | £670.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2008L-50mg | 50mg | £914.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2008L-100mg | 100mg | £1,211.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Lyn peptide inhibitor acetate is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of asthma, allergic, and other eosinophilic disorders.
CAS:
TP2008L
Formula:
C117H188N30O26
Molecular Weight:
2430.98
Pathway:
Immunology/Inflammation
Purity:
0.98
SMILES:
CCCCCCCCCCCCCCCCCC(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(N2CCC[C@H]2C(N)=O)=O)CC(N)=O)=O)=O)[C@H](CC)C)=O)CCCCN)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC3=CNC4=CC=CC=C43)=O)CCCCN)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC5=CC=C(O)C=C5)=O)=O)CC6=CC=C(O)C=C6)=O.CC(O)=O
Target:
IL Receptor
References
Adachi et al (1999) A novel lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J.Immunol. 163 939 PMID:
Adachi et al (1999) The mapping of the Lyn kinase binding site of the common β subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. J.Immunol. 162 1496 PMID: